Healthcare & Biotech

Why I Sold TG Therapeutics Inc (NASDAQ:TGTX) Stock

By: Brian Nichols - October 21, 2017 2:43 AM

Took profits in TGTX stock last week. Here is why.

Also posted in HADE Platform

Imbruvica vs Keytruda Analysis Shows Why Merck (NYSE:MRK) Stock Is Worth Buying Now

By: BNL Staff - September 7, 2017 2:43 AM

Chart shows that Merck (MRK) is likely significantly undervalued based on performance of Keytruda relative to AbbVie and Johnson & Johnson’s (JNJ) Imbruvica

Also posted in HADE Platform, Members, Mergers & Acquisitions

Is Alexion Pharmaceuticals (NASDAQ:ALXN) Stock A Good Investment?

By: BNL Staff - August 21, 2017 2:43 AM

With Soliris prediction through 2018, we explore whether Alexion Pharmaceuticals (NASDAQ:ALXN) is a good investment opportunity.

Also posted in HADE Platform, Members

A Potential Valeant Pharmaceuticals (NYSE:VRX) Catalyst in the Making

By: BNL Staff - August 20, 2017 2:43 AM

Valeant Pharmaceuticals (NYSE:VRX) has a golden opportunity to divest Salix and B&L to cut debt in half. Branded Rx would then drive Valeant stock higher.

Also posted in HADE Platform, Members

Why An ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Buyout Is Likely After Surprisingly Strong Nuplazid Sales

By: BNL Staff - August 8, 2017 2:43 AM

Strong Nuplazid sales confirm that off label usage is very likely, thereby making Acadia Pharmaceuticals (NASDAQ:ACAD) a likely buyout opportunity.

Also posted in HADE Platform, Members, Mergers & Acquisitions